Results 151 to 160 of about 4,157 (182)

TCV-116

Drugs of the Future, 1993
J. Prous, N. Mealy, J. Castañer
openaire   +1 more source

Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine

Biomedical Applications, 1996
T Yashiki, M Motohashi
exaly  

TCV

2008
openaire   +1 more source

Measurement of the magnetic field errors on TCV

Fusion Engineering and Design, 2010
J -M Moret
exaly  

Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats

European Journal of Pharmacology, 1998
Fumio Chatani
exaly  

Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells

European Journal of Pharmacology, 1995
Agapios Sachinidis, Markus Flesch, Yon Ko   +2 more
exaly  

Protective Effects of Candesartan Cilexetil (TCV-116) Against Stroke, Kidney Dysfunction and Cardiac Hypertrophy in Stroke-Prone Spontaneously Hypertensive Rats

Clinical and Experimental Hypertension, 1997
M Ojima, T Sanada, Y Shibouta
exaly  

Neutral beam heating on the TCV tokamak

Fusion Engineering and Design, 2017
Basil Duval, Olivier Sauter, Stefano Coda   +2 more
exaly  

Development of real-time plasma analysis and control algorithms for the TCV tokamak using Simulink

Fusion Engineering and Design, 2014
F Felici, Alessandro Bortolon, Olivier Sauter   +2 more
exaly  

Status, scientific results and technical improvements of the NBH on TCV tokamak

Fusion Engineering and Design, 2019
Roberto Maurizio, Benoit Labit, Matteo Vallar   +2 more
exaly